



CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)

| (in millions) | 2023 | | | | 2024 | | | | 2025 | | | |
|---|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| | Mar 31 | Jun 30 | Sep 30 | Dec 31 | Mar 31 | Jun 30 | Sep 30 | Dec 31 | Mar 31 | Jun 30 | Sep 30 | Dec 31 |
| Assets | | | | | | | | | | | | |
| Cash, cash equivalents and marketable debt securities | \$ 7,200 | \$ 8,001 | \$ 8,021 | \$ 8,428 | \$ 4,718 | \$ 2,772 | \$ 5,037 | \$ 9,991 | \$ 7,926 | \$ 7,126 | \$ 9,354 | \$ 10,605 |
| Accounts receivable, net | 4,162 | 4,229 | 4,790 | 4,660 | 4,669 | 4,663 | 4,587 | 4,420 | 4,388 | 4,781 | 5,095 | 4,913 |
| Inventories | 3,010 | 3,181 | 3,202 | 3,366 | 3,363 | 3,388 | 3,435 | 3,589 | 3,778 | 3,913 | 4,387 | 4,368 |
| Property, plant and equipment, net | 5,479 | 5,540 | 5,572 | 5,317 | 5,321 | 5,346 | 5,391 | 5,414 | 5,421 | 5,459 | 5,500 | 5,606 |
| Intangible assets, net | 28,348 | 27,750 | 27,152 | 26,454 | 23,428 | 22,832 | 20,546 | 19,948 | 19,355 | 18,566 | 17,970 | 16,978 |
| Goodwill | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 |
| Other assets | 5,364 | 5,322 | 5,323 | 5,586 | 6,479 | 6,265 | 7,215 | 7,319 | 7,253 | 7,563 | 7,914 | 8,239 |
| Total assets | \$ 61,876 | \$ 62,337 | \$ 62,373 | \$ 62,125 | \$ 56,292 | \$ 53,579 | \$ 54,525 | \$ 58,995 | \$ 56,434 | \$ 55,721 | \$ 58,533 | \$ 59,023 |
| Liabilities and Stockholders' Equity | | | | | | | | | | | | |
| Current liabilities | \$ 10,528 | \$ 13,964 | \$ 11,945 | \$ 11,280 | \$ 13,015 | \$ 10,781 | \$ 11,725 | \$ 12,004 | \$ 12,344 | \$ 11,189 | \$ 12,298 | \$ 11,813 |
| Long-term liabilities | 30,409 | 27,279 | 28,186 | 28,096 | 25,822 | 24,602 | 24,409 | 27,744 | 25,012 | 24,942 | 24,780 | 24,592 |
| Stockholders' equity | 20,939 | 21,094 | 22,242 | 22,749 | 17,455 | 18,197 | 18,390 | 19,246 | 19,078 | 19,590 | 21,456 | 22,618 |
| Total liabilities and stockholders' equity | \$ 61,876 | \$ 62,337 | \$ 62,373 | \$ 62,125 | \$ 56,292 | \$ 53,579 | \$ 54,525 | \$ 58,995 | \$ 56,434 | \$ 55,721 | \$ 58,533 | \$ 59,023 |

Certain amounts and percentages may not sum or recalculate due to rounding.



CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - GAAP
(unaudited)

| (in millions, except percentages and per share amounts) | 2023 | | | | | 2024 | | | | | 2025 | | | | |
|---|-----------------|-----------------|-----------------|-----------------|-----------------|-------------------|-----------------|-----------------|-----------------|---------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| | Q1 | Q2 | Q3 | Q4 | FY23 | Q1 | Q2 | Q3 | Q4 | FY24 | Q1 | Q2 | Q3 | Q4 | FY25 |
| Revenues: | | | | | | | | | | | | | | | |
| Product sales | \$ 6,306 | \$ 6,564 | \$ 6,994 | \$ 7,070 | \$ 26,934 | \$ 6,647 | \$ 6,912 | \$ 7,515 | \$ 7,536 | \$ 28,610 | \$ 6,613 | \$ 7,054 | \$ 7,345 | \$ 7,903 | \$ 28,915 |
| Royalty, contract and other revenues | 46 | 35 | 56 | 45 | 182 | 39 | 41 | 30 | 33 | 144 | 54 | 27 | 424 | 22 | 527 |
| Total revenues | 6,352 | 6,599 | 7,051 | 7,115 | 27,116 | 6,686 | 6,954 | 7,545 | 7,569 | 28,754 | 6,667 | 7,082 | 7,769 | 7,925 | 29,443 |
| Costs and expenses: | | | | | | | | | | | | | | | |
| Cost of goods sold | 1,401 | 1,442 | 1,565 | 2,090 | 6,498 | 1,552 | 1,544 | 1,574 | 1,581 | 6,251 | 1,540 | 1,501 | 1,569 | 1,623 | 6,234 |
| Research and development expenses | 1,447 | 1,407 | 1,457 | 1,408 | 5,718 | 1,520 | 1,351 | 1,395 | 1,641 | 5,907 | 1,379 | 1,491 | 1,346 | 1,584 | 5,799 |
| Acquired in-process research and development expenses | 481 | 236 | 91 | 347 | 1,155 | 4,131 | 38 | 505 | (11) | 4,663 | 253 | 61 | 170 | 539 | 1,024 |
| In-process research and development impairment | — | — | — | 50 | 50 | 2,430 | — | 1,750 | — | 4,180 | — | 190 | — | 400 | 590 |
| Selling, general and administrative expenses | 1,319 | 1,849 | 1,315 | 1,608 | 6,090 | 1,375 | 1,377 | 1,433 | 1,906 | 6,091 | 1,258 | 1,365 | 1,357 | 1,794 | 5,774 |
| Total costs and expenses | 4,647 | 4,934 | 4,428 | 5,503 | 19,511 | 11,008 | 4,309 | 6,657 | 5,118 | 27,092 | 4,430 | 4,608 | 4,442 | 5,940 | 19,421 |
| Operating income (loss) | 1,705 | 1,665 | 2,623 | 1,612 | 7,605 | (4,322) | 2,644 | 888 | 2,451 | 1,662 | 2,237 | 2,474 | 3,327 | 1,984 | 10,022 |
| Interest expense | 230 | 230 | 232 | 252 | 944 | 254 | 237 | 238 | 248 | 977 | 260 | 254 | 256 | 255 | 1,024 |
| Other (income) expense, net | 174 | (152) | 72 | (293) | (198) | (91) | 355 | (306) | 35 | (6) | 328 | (208) | (569) | (349) | (798) |
| Income (loss) before income taxes | 1,300 | 1,588 | 2,318 | 1,653 | 6,859 | (4,486) | 2,053 | 956 | 2,168 | 690 | 1,649 | 2,429 | 3,641 | 2,078 | 9,796 |
| Income tax expense (benefit) | 316 | 549 | 146 | 236 | 1,247 | (315) | 438 | (297) | 385 | 211 | 334 | 468 | 589 | (105) | 1,286 |
| Net income (loss) | 985 | 1,039 | 2,172 | 1,417 | 5,613 | (4,170) | 1,614 | 1,253 | 1,783 | 480 | 1,315 | 1,960 | 3,052 | 2,183 | 8,510 |
| Net loss attributable to noncontrolling interest | (26) | (6) | (8) | (12) | (52) | — | — | — | — | — | — | — | — | — | — |
| Net income (loss) attributable to Gilead | \$ 1,010 | \$ 1,045 | \$ 2,180 | \$ 1,429 | \$ 5,665 | \$ (4,170) | \$ 1,614 | \$ 1,253 | \$ 1,783 | \$ 480 | \$ 1,315 | \$ 1,960 | \$ 3,052 | \$ 2,183 | \$ 8,510 |
| Basic earnings (loss) per share attributable to Gilead | \$ 0.81 | \$ 0.84 | \$ 1.75 | \$ 1.15 | \$ 4.54 | \$ (3.34) | \$ 1.29 | \$ 1.00 | \$ 1.43 | \$ 0.38 | \$ 1.06 | \$ 1.57 | \$ 2.46 | \$ 1.76 | \$ 6.84 |
| Diluted earnings (loss) per share attributable to Gilead | \$ 0.80 | \$ 0.83 | \$ 1.73 | \$ 1.14 | \$ 4.50 | \$ (3.34) | \$ 1.29 | \$ 1.00 | \$ 1.42 | \$ 0.38 | \$ 1.04 | \$ 1.56 | \$ 2.43 | \$ 1.74 | \$ 6.78 |
| Shares used in basic earnings (loss) per share attributable to Gilead calculation | 1,248 | 1,249 | 1,248 | 1,248 | 1,248 | 1,247 | 1,247 | 1,247 | 1,248 | 1,247 | 1,246 | 1,245 | 1,243 | 1,242 | 1,244 |
| Shares used in diluted earnings (loss) per share attributable to Gilead calculation | 1,261 | 1,258 | 1,257 | 1,256 | 1,258 | 1,247 | 1,251 | 1,254 | 1,259 | 1,255 | 1,259 | 1,255 | 1,254 | 1,253 | 1,255 |
| Supplemental Information: | | | | | | | | | | | | | | | |
| Cash dividends declared per share | \$ 0.75 | \$ 0.75 | \$ 0.75 | \$ 0.75 | \$ 3.00 | \$ 0.77 | \$ 0.77 | \$ 0.77 | \$ 0.77 | \$ 3.08 | \$ 0.79 | \$ 0.79 | \$ 0.79 | \$ 0.79 | \$ 3.16 |
| Product gross margin | 77.8 % | 78.0 % | 77.6 % | 70.4 % | 75.9 % | 76.6 % | 77.7 % | 79.1 % | 79.0 % | 78.2 % | 76.7 % | 78.7 % | 78.6 % | 79.5 % | 78.4 % |
| Research and development expenses as a % of revenues | 22.8 % | 21.3 % | 20.7 % | 19.8 % | 21.1 % | 22.7 % | 19.4 % | 18.5 % | 21.7 % | 20.5 % | 20.7 % | 21.1 % | 17.3 % | 20.0 % | 19.7 % |
| Selling, general and administrative expenses as a % of revenues | 20.8 % | 28.0 % | 18.6 % | 22.6 % | 22.5 % | 20.6 % | 19.8 % | 19.0 % | 25.2 % | 21.2 % | 18.9 % | 19.3 % | 17.5 % | 22.6 % | 19.6 % |
| Operating margin | 26.8 % | 25.2 % | 37.2 % | 22.7 % | 28.0 % | (64.6)% | 38.0 % | 11.8 % | 32.4 % | 5.8 % | 33.6 % | 34.9 % | 42.8 % | 25.0 % | 34.0 % |
| Effective tax rate | 24.3 % | 34.6 % | 6.3 % | 14.3 % | 18.2 % | 7.0 % | 21.4 % | (31.1)% | 17.8 % | 30.5 % | 20.2 % | 19.3 % | 16.2 % | (5.0)% | 13.1 % |

Certain amounts and percentages may not sum or recalculate due to rounding.



SELECTED CASH FLOW INFORMATION
(unaudited)

| (in millions) | 2023 | | | | | 2024 | | | | | 2025 | | | | |
|--|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| | Q1 | Q2 | Q3 | Q4 | FY23 | Q1 | Q2 | Q3 | Q4 | FY24 | Q1 | Q2 | Q3 | Q4 | FY25 |
| Net cash provided by operating activities | \$ 1,744 | \$ 2,337 | \$ 1,756 | \$ 2,168 | \$ 8,006 | \$ 2,219 | \$ 1,325 | \$ 4,309 | \$ 2,975 | \$10,828 | \$ 1,757 | \$ 827 | \$ 4,109 | \$ 3,326 | \$10,019 |
| Net cash used in investing activities | (826) | (483) | (229) | (726) | (2,265) | (2,207) | (307) | (710) | (225) | (3,449) | (415) | (2,116) | (427) | (1,835) | (4,793) |
| Net cash (used in) provided by financing activities | (1,406) | (1,101) | (1,518) | (1,100) | (5,125) | (1,361) | (2,953) | (1,379) | 2,260 | (3,433) | (3,426) | (1,566) | (1,490) | (1,263) | (7,745) |
| Effect of exchange rate changes on cash and cash equivalents | 13 | 14 | (7) | 37 | 57 | (18) | (11) | 44 | (55) | (40) | 19 | 73 | (5) | 5 | 92 |
| Net change in cash and cash equivalents | (476) | 768 | 1 | 380 | 673 | (1,367) | (1,947) | 2,265 | 4,954 | 3,906 | (2,065) | (2,782) | 2,187 | 233 | (2,428) |
| Cash and cash equivalents, beginning of period | 5,412 | 4,936 | 5,704 | 5,705 | 5,412 | 6,085 | 4,718 | 2,772 | 5,037 | 6,085 | 9,991 | 7,926 | 5,144 | 7,330 | 9,991 |
| Cash and cash equivalents, end of period | <u>\$ 4,936</u> | <u>\$ 5,704</u> | <u>\$ 5,705</u> | <u>\$ 6,085</u> | <u>\$ 6,085</u> | <u>\$ 4,718</u> | <u>\$ 2,772</u> | <u>\$ 5,037</u> | <u>\$ 9,991</u> | <u>\$ 9,991</u> | <u>\$ 7,926</u> | <u>\$ 5,144</u> | <u>\$ 7,330</u> | <u>\$ 7,564</u> | <u>\$ 7,564</u> |

| (in millions) | 2023 | | | | | 2024 | | | | | 2025 | | | | |
|--|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|---------------|-----------------|-----------------|-----------------|
| | Q1 | Q2 | Q3 | Q4 | FY23 | Q1 | Q2 | Q3 | Q4 | FY24 | Q1 | Q2 | Q3 | Q4 | FY25 |
| Net cash provided by operating activities | \$ 1,744 | \$ 2,337 | \$ 1,756 | \$ 2,168 | \$ 8,006 | \$ 2,219 | \$ 1,325 | \$ 4,309 | \$ 2,975 | \$10,828 | \$ 1,757 | \$ 827 | \$ 4,109 | \$ 3,326 | \$10,019 |
| Purchases of property, plant and equipment | (109) | (139) | (122) | (214) | (585) | (105) | (130) | (140) | (147) | (523) | (104) | (107) | (147) | (205) | (563) |
| Free cash flow ⁽¹⁾ | <u>\$ 1,635</u> | <u>\$ 2,199</u> | <u>\$ 1,633</u> | <u>\$ 1,954</u> | <u>\$ 7,421</u> | <u>\$ 2,114</u> | <u>\$ 1,195</u> | <u>\$ 4,169</u> | <u>\$ 2,828</u> | <u>\$10,305</u> | <u>\$ 1,653</u> | <u>\$ 720</u> | <u>\$ 3,962</u> | <u>\$ 3,121</u> | <u>\$ 9,456</u> |

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section of our Press Release, issued by Gilead Sciences, Inc. on February 10, 2026 on Form 8-K, which is available on <http://investors.gilead.com>.



NON-GAAP FINANCIAL INFORMATION⁽¹⁾
(unaudited)

| (in millions, except percentages and per share amounts) | 2023 | | | | | 2024 | | | | | 2025 | | | | |
|--|---------|---------|---------|----------|----------|-----------|---------|---------|---------|----------|---------|---------|---------|---------|----------|
| | Q1 | Q2 | Q3 | Q4 | FY23 | Q1 | Q2 | Q3 | Q4 | FY24 | Q1 | Q2 | Q3 | Q4 | FY25 |
| Non-GAAP: | | | | | | | | | | | | | | | |
| Cost of goods sold | \$ 871 | \$ 861 | \$ 985 | \$ 980 | \$3,697 | \$ 974 | \$ 965 | \$ 995 | \$1,002 | \$3,936 | \$ 961 | \$ 922 | \$ 992 | \$1,044 | \$3,919 |
| Research and development expenses | \$1,439 | \$1,377 | \$1,453 | \$1,452 | \$5,720 | \$1,403 | \$1,335 | \$1,382 | \$1,612 | \$5,732 | \$1,338 | \$1,450 | \$1,334 | \$1,565 | \$5,687 |
| Acquired in-process research and development expenses | \$ 481 | \$ 236 | \$ 91 | \$ 347 | \$1,155 | \$4,131 | \$ 38 | \$ 505 | \$ (11) | \$4,663 | \$ 253 | \$ 61 | \$ 170 | \$ 539 | \$1,024 |
| Selling, general and administrative expenses | \$1,318 | \$1,848 | \$1,298 | \$1,597 | \$6,060 | \$1,295 | \$1,351 | \$1,405 | \$1,852 | \$5,903 | \$1,222 | \$1,358 | \$1,351 | \$1,688 | \$5,619 |
| Other (income) expense, net | \$ (82) | \$ (83) | \$ (96) | \$ (104) | \$ (365) | \$ (104) | \$ (37) | \$ (48) | \$ (91) | \$ (279) | \$ (98) | \$ (66) | \$ (87) | \$ (97) | \$ (348) |
| Diluted earnings (loss) per share | \$ 1.37 | \$ 1.34 | \$ 2.29 | \$ 1.72 | \$ 6.72 | \$ (1.32) | \$ 2.01 | \$ 2.02 | \$ 1.90 | \$ 4.62 | \$ 1.81 | \$ 2.01 | \$ 2.47 | \$ 1.86 | \$ 8.15 |
| Shares used in non-GAAP diluted earnings (loss) per share attributable to Gilead calculation | 1,261 | 1,258 | 1,257 | 1,256 | 1,258 | 1,247 | 1,251 | 1,254 | 1,259 | 1,255 | 1,259 | 1,255 | 1,254 | 1,253 | 1,255 |
| Product gross margin | 86.2 % | 86.9 % | 85.9 % | 86.1 % | 86.3 % | 85.4 % | 86.0 % | 86.8 % | 86.7 % | 86.2 % | 85.5 % | 86.9 % | 86.5 % | 86.8 % | 86.4 % |
| Research and development expenses as a % of revenues | 22.6 % | 20.9 % | 20.6 % | 20.4 % | 21.1 % | 21.0 % | 19.2 % | 18.3 % | 21.3 % | 19.9 % | 20.1 % | 20.5 % | 17.2 % | 19.7 % | 19.3 % |
| Selling, general and administrative expenses as a % of revenues | 20.7 % | 28.0 % | 18.4 % | 22.4 % | 22.3 % | 19.4 % | 19.4 % | 18.6 % | 24.5 % | 20.5 % | 18.3 % | 19.2 % | 17.4 % | 21.3 % | 19.1 % |
| Operating margin | 35.3 % | 34.5 % | 45.7 % | 38.5 % | 38.7 % | (16.7)% | 47.0 % | 43.2 % | 41.1 % | 29.6 % | 43.4 % | 46.5 % | 50.5 % | 39.0 % | 44.8 % |
| Effective tax rate | 18.9 % | 21.0 % | 7.0 % | 17.1 % | 15.2 % | (29.8)% | 17.8 % | 17.5 % | 19.2 % | 25.9 % | 16.3 % | 18.8 % | 17.5 % | 20.5 % | 18.3 % |

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ Please refer to our disclosures in the Non-GAAP Financial Information section of our Press Release, issued by Gilead Sciences, Inc. on February 10, 2026 on Form 8-K, which is available on <http://investors.gilead.com>. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 5-7.



RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(unaudited)

| (in millions, except percentages and per share amounts) | 2023 | | | | | 2024 | | | | | 2025 | | | | |
|---|----------|----------|----------|----------|----------|------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| | Q1 | Q2 | Q3 | Q4 | FY23 | Q1 | Q2 | Q3 | Q4 | FY24 | Q1 | Q2 | Q3 | Q4 | FY25 |
| Cost of goods sold reconciliation: | | | | | | | | | | | | | | | |
| GAAP cost of goods sold | \$ 1,401 | \$ 1,442 | \$ 1,565 | \$ 2,090 | \$ 6,498 | \$ 1,552 | \$ 1,544 | \$ 1,574 | \$ 1,581 | \$ 6,251 | \$ 1,540 | \$ 1,501 | \$ 1,569 | \$ 1,623 | \$ 6,234 |
| Acquisition-related – amortization ⁽¹⁾ | (530) | (581) | (581) | (580) | (2,271) | (579) | (579) | (579) | (579) | (2,316) | (579) | (579) | (577) | (576) | (2,310) |
| Restructuring | — | — | — | (479) | (479) | — | — | — | — | — | — | — | — | (4) | (4) |
| Other ⁽²⁾ | — | — | — | (51) | (51) | — | — | — | — | — | — | — | — | — | — |
| Non-GAAP cost of goods sold | \$ 871 | \$ 861 | \$ 985 | \$ 980 | \$ 3,697 | \$ 974 | \$ 965 | \$ 995 | \$ 1,002 | \$ 3,936 | \$ 961 | \$ 922 | \$ 992 | \$ 1,044 | \$ 3,919 |
| Product gross margin reconciliation: | | | | | | | | | | | | | | | |
| GAAP product gross margin | 77.8 % | 78.0 % | 77.6 % | 70.4 % | 75.9 % | 76.6 % | 77.7 % | 79.1 % | 79.0 % | 78.2 % | 76.7 % | 78.7 % | 78.6 % | 79.5 % | 78.4 % |
| Acquisition-related – amortization ⁽¹⁾ | 8.4 % | 8.8 % | 8.3 % | 8.2 % | 8.4 % | 8.7 % | 8.4 % | 7.7 % | 7.7 % | 8.1 % | 8.8 % | 8.2 % | 7.9 % | 7.3 % | 8.0 % |
| Restructuring | — % | — % | — % | 6.8 % | 1.8 % | — % | — % | — % | — % | — % | — % | — % | — % | — % | — % |
| Other ⁽²⁾ | — % | — % | — % | 0.7 % | 0.2 % | — % | — % | — % | — % | — % | — % | — % | — % | — % | — % |
| Non-GAAP product gross margin | 86.2 % | 86.9 % | 85.9 % | 86.1 % | 86.3 % | 85.4 % | 86.0 % | 86.8 % | 86.7 % | 86.2 % | 85.5 % | 86.9 % | 86.5 % | 86.8 % | 86.4 % |
| Research and development expenses reconciliation: | | | | | | | | | | | | | | | |
| GAAP research and development expenses | \$ 1,447 | \$ 1,407 | \$ 1,457 | \$ 1,408 | \$ 5,718 | \$ 1,520 | \$ 1,351 | \$ 1,395 | \$ 1,641 | \$ 5,907 | \$ 1,379 | \$ 1,491 | \$ 1,346 | \$ 1,584 | \$ 5,799 |
| Acquisition-related – other costs ⁽³⁾ | (8) | (30) | 1 | 59 | 22 | (66) | (3) | (9) | — | (78) | (2) | (35) | (4) | (3) | (43) |
| Restructuring | — | — | (5) | (15) | (20) | (50) | (13) | (5) | (30) | (98) | (38) | (6) | (8) | (16) | (69) |
| Non-GAAP research and development expenses | \$ 1,439 | \$ 1,377 | \$ 1,453 | \$ 1,452 | \$ 5,720 | \$ 1,403 | \$ 1,335 | \$ 1,382 | \$ 1,612 | \$ 5,732 | \$ 1,338 | \$ 1,450 | \$ 1,334 | \$ 1,565 | \$ 5,687 |
| IPR&D impairment reconciliation: | | | | | | | | | | | | | | | |
| GAAP IPR&D impairment | \$ — | \$ — | \$ — | \$ 50 | \$ 50 | \$ 2,430 | \$ — | \$ 1,750 | \$ — | \$ 4,180 | \$ — | \$ 190 | \$ — | \$ 400 | \$ 590 |
| IPR&D impairment | — | — | — | (50) | (50) | (2,430) | — | (1,750) | — | (4,180) | — | (190) | — | (400) | (590) |
| Non-GAAP IPR&D impairment | \$ — | \$ — | \$ — | \$ — | \$ — | \$ — | \$ — | \$ — | \$ — | \$ — | \$ — | \$ — | \$ — | \$ — | \$ — |
| Selling, general and administrative expenses reconciliation: | | | | | | | | | | | | | | | |
| GAAP selling, general and administrative expenses | \$ 1,319 | \$ 1,849 | \$ 1,315 | \$ 1,608 | \$ 6,090 | \$ 1,375 | \$ 1,377 | \$ 1,433 | \$ 1,906 | \$ 6,091 | \$ 1,258 | \$ 1,365 | \$ 1,357 | \$ 1,794 | \$ 5,774 |
| Acquisition-related – other costs ⁽³⁾ | (1) | (1) | — | — | (2) | (67) | (17) | (5) | (8) | (97) | — | — | — | — | — |
| Restructuring | — | — | (17) | (11) | (28) | (13) | (8) | (23) | (46) | (91) | (36) | (7) | (5) | (17) | (65) |
| Other ⁽²⁾ | — | — | — | — | — | — | — | — | — | — | — | — | — | (89) | (89) |
| Non-GAAP selling, general and administrative expenses | \$ 1,318 | \$ 1,848 | \$ 1,298 | \$ 1,597 | \$ 6,060 | \$ 1,295 | \$ 1,351 | \$ 1,405 | \$ 1,852 | \$ 5,903 | \$ 1,222 | \$ 1,358 | \$ 1,351 | \$ 1,688 | \$ 5,619 |
| Operating income (loss) reconciliation: | | | | | | | | | | | | | | | |
| GAAP operating income (loss) | \$ 1,705 | \$ 1,665 | \$ 2,623 | \$ 1,612 | \$ 7,605 | \$ (4,322) | \$ 2,644 | \$ 888 | \$ 2,451 | \$ 1,662 | \$ 2,237 | \$ 2,474 | \$ 3,327 | \$ 1,984 | \$10,022 |
| Acquisition-related – amortization ⁽¹⁾ | 530 | 581 | 581 | 580 | 2,271 | 579 | 579 | 579 | 579 | 2,316 | 579 | 579 | 577 | 576 | 2,310 |
| Acquisition-related – other costs ⁽³⁾ | 9 | 31 | (1) | (59) | (20) | 133 | 21 | 13 | 8 | 174 | 2 | 35 | 4 | 3 | 43 |
| Restructuring | — | — | 22 | 505 | 527 | 63 | 21 | 28 | 76 | 188 | 74 | 13 | 14 | 37 | 138 |
| IPR&D impairment | — | — | — | 50 | 50 | 2,430 | — | 1,750 | — | 4,180 | — | 190 | — | 400 | 590 |
| Other ⁽²⁾ | — | — | — | 51 | 51 | — | — | — | — | — | — | — | — | 89 | 89 |
| Non-GAAP operating income (loss) | \$ 2,243 | \$ 2,277 | \$ 3,224 | \$ 2,739 | \$10,484 | \$ (1,117) | \$ 3,265 | \$ 3,258 | \$ 3,114 | \$ 8,520 | \$ 2,893 | \$ 3,290 | \$ 3,921 | \$ 3,089 | \$13,193 |
| Operating margin reconciliation: | | | | | | | | | | | | | | | |
| GAAP operating margin | 26.8 % | 25.2 % | 37.2 % | 22.7 % | 28.0 % | (64.6)% | 38.0 % | 11.8 % | 32.4 % | 5.8 % | 33.6 % | 34.9 % | 42.8 % | 25.0 % | 34.0 % |
| Acquisition-related – amortization ⁽¹⁾ | 8.3 % | 8.8 % | 8.2 % | 8.1 % | 8.4 % | 8.7 % | 8.3 % | 7.7 % | 7.6 % | 8.1 % | 8.7 % | 8.2 % | 7.4 % | 7.3 % | 7.8 % |
| Acquisition-related – other costs ⁽³⁾ | 0.1 % | 0.5 % | — % | (0.8)% | (0.1)% | 2.0 % | 0.3 % | 0.2 % | 0.1 % | 0.6 % | — % | 0.5 % | — % | — % | 0.1 % |
| Restructuring | — % | — % | 0.3 % | 7.1 % | 1.9 % | 0.9 % | 0.3 % | 0.4 % | 1.0 % | 0.7 % | 1.1 % | 0.2 % | 0.2 % | 0.5 % | 0.5 % |
| IPR&D impairment | — % | — % | — % | 0.7 % | 0.2 % | 36.3 % | — % | 23.2 % | — % | 14.5 % | — % | 2.7 % | — % | 5.0 % | 2.0 % |
| Other ⁽²⁾ | — % | — % | — % | 0.7 % | 0.2 % | — % | — % | — % | — % | — % | — % | — % | — % | 1.1 % | 0.3 % |
| Non-GAAP operating margin | 35.3 % | 34.5 % | 45.7 % | 38.5 % | 38.7 % | (16.7)% | 47.0 % | 43.2 % | 41.1 % | 29.6 % | 43.4 % | 46.5 % | 50.5 % | 39.0 % | 44.8 % |
| Other (income) expense, net reconciliation: | | | | | | | | | | | | | | | |
| GAAP other (income) expense, net | \$ 174 | \$ (152) | \$ 72 | \$ (293) | \$ (198) | \$ (91) | \$ 355 | \$ (306) | \$ 35 | \$ (6) | \$ 328 | \$ (208) | \$ (569) | \$ (349) | \$ (798) |
| (Loss) gain from equity securities, net | (256) | 69 | (168) | 189 | (167) | (14) | (392) | 258 | (126) | (274) | (426) | 142 | 483 | 252 | 451 |
| Non-GAAP other (income) expense, net | \$ (82) | \$ (83) | \$ (96) | \$ (104) | \$ (365) | \$ (104) | \$ (37) | \$ (48) | \$ (91) | \$ (279) | \$ (98) | \$ (66) | \$ (87) | \$ (97) | \$ (348) |

Questions? Contact Investor_Relations@gilead.com



RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)
(unaudited)

| (in millions, except percentages and per share amounts) | 2023 | | | | | 2024 | | | | | 2025 | | | | |
|---|-----------------|-----------------|-----------------|-----------------|-----------------|-------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| | Q1 | Q2 | Q3 | Q4 | FY23 | Q1 | Q2 | Q3 | Q4 | FY24 | Q1 | Q2 | Q3 | Q4 | FY25 |
| Income (loss) before income taxes reconciliation: | | | | | | | | | | | | | | | |
| GAAP income (loss) before income taxes | \$ 1,300 | \$ 1,588 | \$ 2,318 | \$ 1,653 | \$ 6,859 | \$ (4,486) | \$ 2,053 | \$ 956 | \$ 2,168 | \$ 690 | \$ 1,649 | \$ 2,429 | \$ 3,641 | \$ 2,078 | \$ 9,796 |
| Acquisition-related – amortization ⁽¹⁾ | 530 | 581 | 581 | 580 | 2,271 | 579 | 579 | 579 | 579 | 2,316 | 579 | 579 | 577 | 576 | 2,310 |
| Acquisition-related – other costs ⁽³⁾ | 9 | 31 | (1) | (59) | (20) | 133 | 21 | 13 | 8 | 174 | 2 | 35 | 4 | 3 | 43 |
| Restructuring | — | — | 22 | 505 | 527 | 63 | 21 | 28 | 76 | 188 | 74 | 13 | 14 | 37 | 138 |
| IPR&D impairment | — | — | — | 50 | 50 | 2,430 | — | 1,750 | — | 4,180 | — | 190 | — | 400 | 590 |
| Loss (gain) from equity securities, net | 256 | (69) | 168 | (189) | 167 | 14 | 392 | (258) | 126 | 274 | 426 | (142) | (483) | (252) | (451) |
| Other ⁽²⁾ | — | — | — | 51 | 51 | — | — | — | — | — | — | — | — | 89 | 89 |
| Non-GAAP income (loss) before income taxes | <u>\$ 2,096</u> | <u>\$ 2,131</u> | <u>\$ 3,088</u> | <u>\$ 2,591</u> | <u>\$ 9,905</u> | <u>\$ (1,267)</u> | <u>\$ 3,065</u> | <u>\$ 3,068</u> | <u>\$ 2,956</u> | <u>\$ 7,822</u> | <u>\$ 2,731</u> | <u>\$ 3,103</u> | <u>\$ 3,752</u> | <u>\$ 2,930</u> | <u>\$12,517</u> |
| Income tax expense reconciliation: | | | | | | | | | | | | | | | |
| GAAP income tax (benefit) expense | \$ 316 | \$ 549 | \$ 146 | \$ 236 | \$ 1,247 | \$ (315) | \$ 438 | \$ (297) | \$ 385 | \$ 211 | \$ 334 | \$ 468 | \$ 589 | \$ (105) | \$ 1,286 |
| Income tax effect of non-GAAP adjustments: | | | | | | | | | | | | | | | |
| Acquisition-related – amortization ⁽¹⁾ | 107 | 120 | 120 | 119 | 466 | 121 | 121 | 121 | 121 | 484 | 120 | 120 | 120 | 118 | 478 |
| Acquisition-related – other costs ⁽³⁾ | 3 | 5 | — | 1 | 9 | 30 | 7 | 2 | 2 | 41 | — | — | — | — | — |
| Restructuring | — | — | 5 | 90 | 95 | 10 | 7 | 4 | 16 | 37 | 14 | 2 | 3 | 7 | 25 |
| IPR&D impairment | — | — | — | 15 | 15 | 611 | — | 440 | — | 1,051 | — | 51 | — | 87 | 137 |
| (Gain) loss from equity securities, net | (1) | 1 | 4 | (18) | (14) | (39) | 33 | (46) | 13 | (39) | 20 | (11) | (43) | 14 | (20) |
| Discrete and related tax charges ⁽⁴⁾ | (29) | (227) | (58) | (12) | (326) | (39) | (60) | 314 | 29 | 243 | (42) | (48) | (11) | 454 | 353 |
| Other ⁽²⁾ | — | — | — | 11 | 11 | — | — | — | — | — | — | — | — | 27 | 27 |
| Non-GAAP income tax expense | <u>\$ 396</u> | <u>\$ 448</u> | <u>\$ 216</u> | <u>\$ 442</u> | <u>\$ 1,503</u> | <u>\$ 379</u> | <u>\$ 546</u> | <u>\$ 538</u> | <u>\$ 566</u> | <u>\$ 2,028</u> | <u>\$ 446</u> | <u>\$ 583</u> | <u>\$ 657</u> | <u>\$ 601</u> | <u>\$ 2,287</u> |
| Effective tax rate reconciliation: | | | | | | | | | | | | | | | |
| GAAP effective tax rate | 24.3 % | 34.6 % | 6.3 % | 14.3 % | 18.2 % | 7.0 % | 21.4 % | (31.1)% | 17.8 % | 30.5 % | 20.2 % | 19.3 % | 16.2 % | (5.0)% | 13.1 % |
| Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments ⁽⁴⁾ | (5.4)% | (13.5)% | 0.7 % | 2.8 % | (3.0)% | (36.8)% | (3.5)% | 48.6 % | 1.4 % | (4.6)% | (3.9)% | (0.5)% | 1.3 % | 25.6 % | 5.1 % |
| Non-GAAP effective tax rate | <u>18.9 %</u> | <u>21.0 %</u> | <u>7.0 %</u> | <u>17.1 %</u> | <u>15.2 %</u> | <u>(29.8)%</u> | <u>17.8 %</u> | <u>17.5 %</u> | <u>19.2 %</u> | <u>25.9 %</u> | <u>16.3 %</u> | <u>18.8 %</u> | <u>17.5 %</u> | <u>20.5 %</u> | <u>18.3 %</u> |
| Net income (loss) attributable to Gilead reconciliation: | | | | | | | | | | | | | | | |
| GAAP net income (loss) attributable to Gilead | \$ 1,010 | \$ 1,045 | \$ 2,180 | \$ 1,429 | \$ 5,665 | \$ (4,170) | \$ 1,614 | \$ 1,253 | \$ 1,783 | \$ 480 | \$ 1,315 | \$ 1,960 | \$ 3,052 | \$ 2,183 | \$ 8,510 |
| Acquisition-related – amortization ⁽¹⁾ | 422 | 461 | 461 | 460 | 1,805 | 458 | 458 | 458 | 458 | 1,832 | 459 | 459 | 457 | 458 | 1,832 |
| Acquisition-related – other costs ⁽³⁾ | 6 | 26 | (1) | (59) | (29) | 103 | 14 | 11 | 6 | 134 | 2 | 35 | 4 | 3 | 43 |
| Restructuring | — | — | 17 | 414 | 431 | 54 | 14 | 24 | 59 | 151 | 61 | 11 | 11 | 30 | 113 |
| IPR&D impairment | — | — | — | 35 | 35 | 1,819 | — | 1,310 | — | 3,129 | — | 139 | — | 313 | 453 |
| Loss (gain) from equity securities, net | 257 | (70) | 164 | (171) | 180 | 53 | 359 | (212) | 113 | 313 | 406 | (131) | (440) | (266) | (431) |
| Discrete and related tax charges ⁽⁴⁾ | 29 | 227 | 58 | 12 | 326 | 39 | 60 | (314) | (29) | (243) | 42 | 48 | 11 | (454) | (353) |
| Other ⁽²⁾ | — | — | — | 40 | 40 | — | — | — | — | — | — | — | — | 63 | 63 |
| Non-GAAP net income (loss) attributable to Gilead | <u>\$ 1,725</u> | <u>\$ 1,688</u> | <u>\$ 2,879</u> | <u>\$ 2,161</u> | <u>\$ 8,454</u> | <u>\$ (1,644)</u> | <u>\$ 2,519</u> | <u>\$ 2,531</u> | <u>\$ 2,390</u> | <u>\$ 5,795</u> | <u>\$ 2,285</u> | <u>\$ 2,521</u> | <u>\$ 3,095</u> | <u>\$ 2,329</u> | <u>\$10,230</u> |
| Diluted earnings (loss) per share reconciliation: | | | | | | | | | | | | | | | |
| GAAP diluted earnings (loss) per share | \$ 0.80 | \$ 0.83 | \$ 1.73 | \$ 1.14 | \$ 4.50 | \$ (3.34) | \$ 1.29 | \$ 1.00 | \$ 1.42 | \$ 0.38 | \$ 1.04 | \$ 1.56 | \$ 2.43 | \$ 1.74 | \$ 6.78 |
| Acquisition-related – amortization ⁽¹⁾ | 0.33 | 0.37 | 0.37 | 0.37 | 1.43 | 0.37 | 0.37 | 0.37 | 0.36 | 1.46 | 0.36 | 0.37 | 0.36 | 0.37 | 1.46 |
| Acquisition-related – other costs ⁽³⁾ | 0.01 | 0.02 | — | (0.05) | (0.02) | 0.08 | 0.01 | 0.01 | — | 0.11 | — | 0.03 | — | — | 0.03 |
| Restructuring | — | — | 0.01 | 0.33 | 0.34 | 0.04 | 0.01 | 0.02 | 0.05 | 0.12 | 0.05 | 0.01 | 0.01 | 0.02 | 0.09 |
| IPR&D impairment | — | — | — | 0.03 | 0.03 | 1.46 | — | 1.04 | — | 2.49 | — | 0.11 | — | 0.25 | 0.36 |
| Loss (gain) from equity securities, net | 0.20 | (0.06) | 0.13 | (0.14) | 0.14 | 0.04 | 0.29 | (0.17) | 0.09 | 0.25 | 0.32 | (0.10) | (0.35) | (0.21) | (0.34) |
| Discrete and related tax charges ⁽⁴⁾ | 0.02 | 0.18 | 0.05 | 0.01 | 0.26 | 0.03 | 0.05 | (0.25) | (0.02) | (0.19) | 0.03 | 0.04 | 0.01 | (0.36) | (0.28) |
| Other ⁽²⁾ | — | — | — | 0.03 | 0.03 | — | — | — | — | — | — | — | — | 0.05 | 0.05 |
| Non-GAAP diluted earnings (loss) per share | <u>\$ 1.37</u> | <u>\$ 1.34</u> | <u>\$ 2.29</u> | <u>\$ 1.72</u> | <u>\$ 6.72</u> | <u>\$ (1.32)</u> | <u>\$ 2.01</u> | <u>\$ 2.02</u> | <u>\$ 1.90</u> | <u>\$ 4.62</u> | <u>\$ 1.81</u> | <u>\$ 2.01</u> | <u>\$ 2.47</u> | <u>\$ 1.86</u> | <u>\$ 8.15</u> |

Questions? Contact Investor_Relations@gilead.com



RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)
(unaudited)

| (in millions, except percentages and per share amounts) | 2023 | | | | | 2024 | | | | | 2025 | | | | |
|--|--------|--------|--------|----------|----------|----------|--------|----------|--------|----------|--------|--------|--------|--------|----------|
| | Q1 | Q2 | Q3 | Q4 | FY23 | Q1 | Q2 | Q3 | Q4 | FY24 | Q1 | Q2 | Q3 | Q4 | FY25 |
| Non-GAAP adjustment summary: | | | | | | | | | | | | | | | |
| Cost of goods sold adjustments | \$ 530 | \$ 581 | \$ 581 | \$ 1,110 | \$ 2,801 | \$ 579 | \$ 579 | \$ 579 | \$ 579 | \$ 2,315 | \$ 579 | \$ 579 | \$ 577 | \$ 579 | \$ 2,314 |
| Research and development expenses adjustments | 8 | 30 | 4 | (44) | (2) | 117 | 16 | 13 | 29 | 176 | 40 | 41 | 12 | 19 | 112 |
| IPR&D impairment adjustments | — | — | — | 50 | 50 | 2,430 | — | 1,750 | — | 4,180 | — | 190 | — | 400 | 590 |
| Selling, general and administrative expenses adjustments | 1 | 1 | 17 | 11 | 30 | 80 | 26 | 28 | 54 | 188 | 36 | 7 | 5 | 106 | 155 |
| Total non-GAAP adjustments to costs and expenses | 539 | 612 | 602 | 1,127 | 2,879 | 3,205 | 620 | 2,370 | 663 | 6,858 | 656 | 817 | 594 | 1,104 | 3,171 |
| Other (income) expense, net, adjustments | 256 | (69) | 168 | (189) | 167 | 14 | 392 | (258) | 126 | 274 | 426 | (142) | (483) | (252) | (451) |
| Total non-GAAP adjustments before income taxes | 795 | 543 | 770 | 938 | 3,046 | 3,219 | 1,012 | 2,113 | 789 | 7,132 | 1,082 | 675 | 112 | 852 | 2,720 |
| Income tax effect of non-GAAP adjustments above | (109) | (126) | (129) | (218) | (583) | (732) | (168) | (521) | (152) | (1,574) | (154) | (162) | (79) | (252) | (647) |
| Discrete and related tax charges ⁽⁴⁾ | 29 | 227 | 58 | 12 | 326 | 39 | 60 | (314) | (29) | (243) | 42 | 48 | 11 | (454) | (353) |
| Total non-GAAP adjustments after tax | \$ 715 | \$ 644 | \$ 699 | \$ 732 | \$ 2,789 | \$ 2,526 | \$ 905 | \$ 1,278 | \$ 607 | \$ 5,315 | \$ 970 | \$ 560 | \$ 43 | \$ 146 | \$ 1,719 |

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ Relates to amortization of acquired intangibles and inventory step-up charges.

⁽²⁾ The adjustment in Cost of goods sold relates to a write-off of an intangible asset related to the restructuring of our collaboration with Galapagos NV during the fourth quarter of 2023. The adjustment in Selling, general and administrative expenses relates to donations of equity securities to the Gilead Foundation, a California nonprofit organization, during the fourth quarter of 2025.

⁽³⁾ Relates primarily to integration expenses, contingent consideration fair value adjustments and other expenses associated with Gilead's recent acquisitions.

⁽⁴⁾ Represents discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and in-process research and development, transfers of intangible assets from a foreign subsidiary to Ireland and the United States, and legal entity restructurings.



TOTAL REVENUE SUMMARY
(unaudited)

| (in millions) | 2023 | | | | | 2024 | | | | | 2025 | | | | |
|---------------------------------------|----------------|----------------|----------------|----------------|-----------------|----------------|----------------|----------------|----------------|-----------------|----------------|----------------|----------------|----------------|-----------------|
| | Q1 | Q2 | Q3 | Q4 | FY23 | Q1 | Q2 | Q3 | Q4 | FY24 | Q1 | Q2 | Q3 | Q4 | FY25 |
| Product sales ⁽¹⁾ : | | | | | | | | | | | | | | | |
| HIV | \$4,190 | \$4,626 | \$4,667 | \$4,693 | \$18,175 | \$4,342 | \$4,745 | \$5,073 | \$5,452 | \$19,612 | \$4,587 | \$5,088 | \$5,277 | \$5,801 | \$20,752 |
| Liver Disease | 675 | 711 | 706 | 691 | 2,784 | 737 | 832 | 733 | 719 | 3,021 | 758 | 795 | 819 | 844 | 3,217 |
| Oncology | 670 | 728 | 769 | 765 | 2,932 | 789 | 841 | 816 | 843 | 3,289 | 757 | 849 | 788 | 842 | 3,236 |
| Other | 199 | 243 | 216 | 201 | 859 | 224 | 280 | 201 | 184 | 889 | 209 | 202 | 184 | 205 | 799 |
| Total product sales excluding Veklury | 5,733 | 6,308 | 6,358 | 6,350 | 24,750 | 6,092 | 6,698 | 6,823 | 7,198 | 26,811 | 6,311 | 6,934 | 7,068 | 7,691 | 28,004 |
| Veklury | 573 | 256 | 636 | 720 | 2,184 | 555 | 214 | 692 | 337 | 1,799 | 302 | 121 | 277 | 212 | 911 |
| Total product sales | 6,306 | 6,564 | 6,994 | 7,070 | 26,934 | 6,647 | 6,912 | 7,515 | 7,536 | 28,610 | 6,613 | 7,054 | 7,345 | 7,903 | 28,915 |
| Royalty, contract and other revenues | 46 | 35 | 56 | 45 | 182 | 39 | 41 | 30 | 33 | 144 | 54 | 27 | 424 | 22 | 527 |
| Total revenues | <u>\$6,352</u> | <u>\$6,599</u> | <u>\$7,051</u> | <u>\$7,115</u> | <u>\$27,116</u> | <u>\$6,686</u> | <u>\$6,954</u> | <u>\$7,545</u> | <u>\$7,569</u> | <u>\$28,754</u> | <u>\$6,667</u> | <u>\$7,082</u> | <u>\$7,769</u> | <u>\$7,925</u> | <u>\$29,443</u> |

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ See Product Sales Summary on pages 9-11 for more details.



PRODUCT SALES SUMMARY
(unaudited)

| (in millions) | 2023 | | | | | 2024 | | | | | 2025 | | | | |
|--|----------|----------|-------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| | Q1 | Q2 | Q3 | Q4 | FY23 | Q1 | Q2 | Q3 | Q4 | FY24 | Q1 | Q2 | Q3 | Q4 | FY25 |
| HIV | | | | | | | | | | | | | | | |
| Biktarvy – U.S. | \$ 2,161 | \$ 2,439 | 2,504 | \$ 2,588 | \$ 9,692 | \$ 2,315 | \$ 2,585 | \$ 2,826 | \$ 3,129 | \$10,855 | \$ 2,474 | \$ 2,799 | \$ 2,940 | \$ 3,255 | \$11,467 |
| Biktarvy – Europe | 304 | 302 | 313 | 333 | 1,253 | 365 | 370 | 375 | 400 | 1,509 | 375 | 429 | 427 | 446 | 1,676 |
| Biktarvy – Rest of World | 212 | 237 | 268 | 188 | 905 | 265 | 277 | 272 | 246 | 1,060 | 301 | 302 | 320 | 268 | 1,190 |
| | 2,677 | 2,979 | 3,085 | 3,109 | 11,850 | 2,946 | 3,232 | 3,472 | 3,774 | 13,423 | 3,150 | 3,530 | 3,686 | 3,968 | 14,334 |
| Descovy – U.S. | 395 | 460 | 460 | 457 | 1,771 | 371 | 434 | 534 | 563 | 1,902 | 538 | 601 | 652 | 768 | 2,559 |
| Descovy – Europe | 25 | 25 | 25 | 25 | 100 | 26 | 25 | 24 | 25 | 100 | 21 | 24 | 23 | 26 | 93 |
| Descovy – Rest of World | 29 | 31 | 26 | 28 | 114 | 29 | 26 | 28 | 28 | 110 | 27 | 28 | 25 | 25 | 105 |
| | 449 | 516 | 511 | 509 | 1,985 | 426 | 485 | 586 | 616 | 2,113 | 586 | 653 | 701 | 819 | 2,758 |
| Genvoya – U.S. | 417 | 455 | 433 | 447 | 1,752 | 332 | 372 | 384 | 410 | 1,498 | 305 | 322 | 323 | 331 | 1,281 |
| Genvoya – Europe | 55 | 56 | 47 | 48 | 205 | 49 | 45 | 44 | 42 | 180 | 40 | 40 | 34 | 34 | 148 |
| Genvoya – Rest of World | 29 | 29 | 23 | 22 | 103 | 21 | 23 | 21 | 18 | 84 | 19 | 16 | 19 | 15 | 69 |
| | 501 | 540 | 503 | 517 | 2,060 | 403 | 440 | 449 | 470 | 1,762 | 364 | 377 | 377 | 380 | 1,498 |
| Odefsey – U.S. | 230 | 267 | 257 | 258 | 1,012 | 223 | 233 | 248 | 252 | 957 | 215 | 221 | 206 | 238 | 881 |
| Odefsey – Europe | 76 | 74 | 74 | 71 | 294 | 76 | 72 | 69 | 74 | 290 | 57 | 66 | 61 | 62 | 246 |
| Odefsey – Rest of World | 11 | 11 | 11 | 11 | 44 | 11 | 10 | 9 | 11 | 41 | 10 | 11 | 10 | 10 | 40 |
| | 317 | 351 | 343 | 340 | 1,350 | 310 | 315 | 326 | 336 | 1,288 | 281 | 298 | 277 | 310 | 1,167 |
| Symtuza - Revenue share ⁽¹⁾ – U.S. | 98 | 84 | 96 | 104 | 382 | 104 | 131 | 103 | 112 | 450 | 82 | 88 | 95 | 98 | 363 |
| Symtuza - Revenue share ⁽¹⁾ – Europe | 36 | 33 | 32 | 32 | 133 | 33 | 34 | 33 | 30 | 130 | 29 | 33 | 26 | 32 | 120 |
| Symtuza - Revenue share ⁽¹⁾ – Rest of World | 4 | 3 | 3 | 3 | 13 | 3 | 3 | 3 | 3 | 12 | 3 | 3 | 3 | 3 | 12 |
| | 138 | 120 | 131 | 139 | 529 | 141 | 168 | 139 | 144 | 592 | 114 | 124 | 124 | 134 | 495 |
| Other HIV ⁽²⁾ – U.S. | 62 | 74 | 56 | 46 | 238 | 60 | 65 | 65 | 67 | 257 | 50 | 65 | 82 | 154 | 352 |
| Other HIV ⁽²⁾ – Europe | 32 | 31 | 28 | 25 | 116 | 45 | 25 | 26 | 33 | 129 | 31 | 33 | 22 | 24 | 109 |
| Other HIV ⁽²⁾ – Rest of World | 13 | 15 | 9 | 9 | 47 | 12 | 15 | 9 | 11 | 48 | 10 | 9 | 9 | 12 | 40 |
| | 108 | 120 | 94 | 79 | 401 | 117 | 105 | 100 | 111 | 434 | 91 | 107 | 112 | 190 | 500 |
| Total HIV – U.S. | 3,364 | 3,778 | 3,807 | 3,899 | 14,848 | 3,405 | 3,821 | 4,161 | 4,532 | 15,918 | 3,664 | 4,096 | 4,299 | 4,845 | 16,904 |
| Total HIV – Europe | 528 | 521 | 519 | 533 | 2,102 | 596 | 571 | 570 | 603 | 2,339 | 553 | 624 | 592 | 624 | 2,392 |
| Total HIV – Rest of World | 298 | 326 | 341 | 261 | 1,226 | 342 | 353 | 342 | 317 | 1,355 | 370 | 368 | 386 | 332 | 1,456 |
| | 4,190 | 4,626 | 4,667 | 4,693 | 18,175 | 4,342 | 4,745 | 5,073 | 5,452 | 19,612 | 4,587 | 5,088 | 5,277 | 5,801 | 20,752 |
| Liver Disease | | | | | | | | | | | | | | | |
| Sofosbuvir/Velpatasvir ⁽³⁾ – U.S. | 204 | 223 | 215 | 216 | 859 | 248 | 267 | 222 | 185 | 922 | 166 | 184 | 146 | 140 | 636 |
| Sofosbuvir/Velpatasvir ⁽³⁾ – Europe | 90 | 84 | 76 | 74 | 323 | 79 | 84 | 67 | 69 | 299 | 80 | 81 | 65 | 66 | 292 |
| Sofosbuvir/Velpatasvir ⁽³⁾ – Rest of World | 90 | 90 | 85 | 89 | 355 | 78 | 126 | 96 | 75 | 374 | 99 | 76 | 97 | 71 | 344 |
| | 385 | 397 | 377 | 378 | 1,537 | 405 | 476 | 385 | 330 | 1,596 | 346 | 342 | 309 | 276 | 1,272 |

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽¹⁾ Represents Gilead's revenue from cobicistat ("C"), emtricitabine ("FTC") and tenofovir alafenamide ("TAF") in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

⁽²⁾ Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada, Tybost and Yeztugo/Yeytuo.

⁽³⁾ Includes Eplclusa and the authorized generic version of Eplclusa sold by Gilead's separate subsidiary, Aseguia Therapeutics LLC ("Aseguia").



PRODUCT SALES SUMMARY (Continued)
(unaudited)

| (in millions) | 2023 | | | | | 2024 | | | | | 2025 | | | | |
|--|------|-----|-----|-----|-------|------|-----|-----|-----|-------|------|-----|-----|-----|-------|
| | Q1 | Q2 | Q3 | Q4 | FY23 | Q1 | Q2 | Q3 | Q4 | FY24 | Q1 | Q2 | Q3 | Q4 | FY25 |
| Vemlidy – U.S. | 87 | 96 | 112 | 115 | 410 | 95 | 117 | 126 | 148 | 486 | 100 | 122 | 136 | 149 | 507 |
| Vemlidy – Europe | 9 | 10 | 9 | 10 | 38 | 11 | 11 | 11 | 11 | 44 | 12 | 13 | 12 | 12 | 49 |
| Vemlidy – Rest of World | 103 | 113 | 106 | 92 | 414 | 119 | 115 | 95 | 100 | 428 | 140 | 117 | 132 | 125 | 514 |
| | 199 | 219 | 228 | 217 | 862 | 225 | 243 | 232 | 260 | 959 | 252 | 252 | 280 | 287 | 1,070 |
| Other Liver Disease ⁽⁴⁾ – U.S. | 27 | 37 | 49 | 39 | 152 | 42 | 47 | 45 | 58 | 192 | 68 | 106 | 132 | 168 | 476 |
| Other Liver Disease ⁽⁴⁾ – Europe | 41 | 37 | 33 | 38 | 150 | 47 | 47 | 54 | 54 | 202 | 76 | 76 | 81 | 96 | 330 |
| Other Liver Disease ⁽⁴⁾ – Rest of World | 23 | 21 | 20 | 19 | 83 | 19 | 19 | 17 | 18 | 73 | 17 | 19 | 17 | 16 | 69 |
| | 91 | 95 | 102 | 96 | 385 | 107 | 113 | 116 | 130 | 467 | 161 | 201 | 231 | 281 | 874 |
| Total Liver Disease – U.S. | 318 | 356 | 376 | 370 | 1,421 | 385 | 431 | 393 | 391 | 1,601 | 335 | 413 | 414 | 457 | 1,619 |
| Total Liver Disease – Europe | 140 | 131 | 119 | 121 | 511 | 137 | 142 | 132 | 134 | 545 | 168 | 170 | 158 | 174 | 671 |
| Total Liver Disease – Rest of World | 217 | 225 | 211 | 200 | 852 | 215 | 259 | 207 | 194 | 876 | 256 | 211 | 247 | 212 | 927 |
| | 675 | 711 | 706 | 691 | 2,784 | 737 | 832 | 733 | 719 | 3,021 | 758 | 795 | 819 | 844 | 3,217 |
| Veklury | | | | | | | | | | | | | | | |
| Veklury – U.S. | 252 | 97 | 258 | 364 | 972 | 315 | 76 | 393 | 108 | 892 | 199 | 51 | 140 | 80 | 470 |
| Veklury – Europe | 111 | 52 | 65 | 181 | 408 | 70 | 53 | 81 | 80 | 284 | 22 | 19 | 43 | 67 | 151 |
| Veklury – Rest of World | 209 | 107 | 313 | 175 | 805 | 169 | 85 | 219 | 150 | 623 | 82 | 50 | 93 | 65 | 290 |
| | 573 | 256 | 636 | 720 | 2,184 | 555 | 214 | 692 | 337 | 1,799 | 302 | 121 | 277 | 212 | 911 |
| Oncology | | | | | | | | | | | | | | | |
| Cell Therapy | | | | | | | | | | | | | | | |
| Tecartus – U.S. | 59 | 56 | 64 | 66 | 245 | 55 | 63 | 63 | 53 | 234 | 40 | 41 | 40 | 32 | 153 |
| Tecartus – Europe | 27 | 29 | 27 | 27 | 110 | 36 | 37 | 29 | 36 | 138 | 31 | 41 | 35 | 51 | 158 |
| Tecartus – Rest of World | 3 | 4 | 4 | 5 | 15 | 8 | 7 | 6 | 10 | 31 | 8 | 9 | 8 | 7 | 32 |
| | 89 | 88 | 96 | 98 | 370 | 100 | 107 | 98 | 98 | 403 | 78 | 92 | 83 | 90 | 344 |
| Yescarta – U.S. | 210 | 217 | 197 | 187 | 811 | 170 | 186 | 145 | 161 | 662 | 160 | 162 | 123 | 151 | 595 |
| Yescarta – Europe | 121 | 133 | 154 | 140 | 547 | 158 | 169 | 182 | 156 | 666 | 149 | 154 | 151 | 143 | 598 |
| Yescarta – Rest of World | 28 | 30 | 40 | 42 | 140 | 52 | 58 | 60 | 72 | 242 | 77 | 77 | 75 | 74 | 303 |
| | 359 | 380 | 391 | 368 | 1,498 | 380 | 414 | 387 | 390 | 1,570 | 386 | 393 | 349 | 368 | 1,495 |
| Total Cell Therapy – U.S. | 269 | 272 | 261 | 253 | 1,055 | 225 | 250 | 208 | 213 | 896 | 200 | 203 | 163 | 183 | 748 |
| Total Cell Therapy – Europe | 148 | 162 | 181 | 167 | 658 | 195 | 206 | 211 | 193 | 804 | 180 | 196 | 186 | 193 | 755 |
| Total Cell Therapy – Rest of World | 31 | 34 | 45 | 46 | 156 | 60 | 66 | 66 | 82 | 274 | 84 | 86 | 83 | 82 | 335 |
| | 448 | 469 | 486 | 466 | 1,869 | 480 | 521 | 485 | 488 | 1,973 | 464 | 485 | 432 | 458 | 1,839 |
| Trodelvy | | | | | | | | | | | | | | | |
| Trodelvy – U.S. | 162 | 189 | 201 | 226 | 777 | 206 | 224 | 226 | 247 | 902 | 181 | 224 | 221 | 251 | 877 |
| Trodelvy – Europe | 54 | 53 | 62 | 48 | 217 | 68 | 69 | 80 | 77 | 294 | 75 | 96 | 89 | 88 | 347 |
| Trodelvy – Rest of World | 6 | 17 | 21 | 24 | 68 | 36 | 26 | 26 | 31 | 119 | 37 | 44 | 47 | 45 | 173 |
| | 222 | 260 | 283 | 299 | 1,063 | 309 | 320 | 332 | 355 | 1,315 | 293 | 364 | 357 | 384 | 1,397 |
| Total Oncology – U.S. | 431 | 462 | 462 | 479 | 1,833 | 431 | 474 | 433 | 461 | 1,798 | 381 | 427 | 384 | 434 | 1,626 |
| Total Oncology – Europe | 202 | 215 | 243 | 216 | 875 | 262 | 275 | 291 | 269 | 1,098 | 255 | 291 | 275 | 281 | 1,102 |
| Total Oncology – Rest of World | 37 | 51 | 65 | 70 | 224 | 96 | 92 | 92 | 113 | 393 | 121 | 131 | 129 | 127 | 508 |
| | 670 | 728 | 769 | 765 | 2,932 | 789 | 841 | 816 | 843 | 3,289 | 757 | 849 | 788 | 842 | 3,236 |

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽⁴⁾ Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi/Lyvdelzi, Sovaldi, Viread and Vosevi.



PRODUCT SALES SUMMARY (Continued)
(unaudited)

| (in millions) | 2023 | | | | | 2024 | | | | | 2025 | | | | |
|--------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| | Q1 | Q2 | Q3 | Q4 | FY23 | Q1 | Q2 | Q3 | Q4 | FY24 | Q1 | Q2 | Q3 | Q4 | FY25 |
| Other | | | | | | | | | | | | | | | |
| AmBisome – U.S. | 6 | 20 | 12 | 4 | 43 | 14 | 17 | 6 | 7 | 44 | 5 | 7 | 2 | 5 | 20 |
| AmBisome – Europe | 60 | 69 | 63 | 68 | 260 | 70 | 69 | 71 | 66 | 276 | 67 | 65 | 69 | 66 | 267 |
| AmBisome – Rest of World | 49 | 61 | 39 | 39 | 189 | 60 | 65 | 52 | 36 | 212 | 66 | 56 | 52 | 47 | 221 |
| | <u>116</u> | <u>151</u> | <u>115</u> | <u>111</u> | <u>492</u> | <u>144</u> | <u>151</u> | <u>130</u> | <u>109</u> | <u>533</u> | <u>139</u> | <u>129</u> | <u>123</u> | <u>118</u> | <u>509</u> |
| Other ⁽⁵⁾ – U.S. | 62 | 64 | 69 | 64 | 261 | 59 | 98 | 47 | 51 | 255 | 47 | 44 | 34 | 52 | 177 |
| Other ⁽⁵⁾ – Europe | 12 | 10 | 9 | 9 | 40 | 9 | 8 | 8 | 8 | 34 | 9 | 8 | 7 | 9 | 32 |
| Other ⁽⁵⁾ – Rest of World | 9 | 17 | 23 | 17 | 66 | 12 | 24 | 16 | 16 | 68 | 14 | 21 | 20 | 26 | 81 |
| | <u>83</u> | <u>92</u> | <u>101</u> | <u>90</u> | <u>367</u> | <u>80</u> | <u>130</u> | <u>71</u> | <u>76</u> | <u>356</u> | <u>70</u> | <u>73</u> | <u>61</u> | <u>87</u> | <u>290</u> |
| Total Other – U.S. | 69 | 85 | 82 | 68 | 304 | 73 | 115 | 53 | 59 | 299 | 52 | 52 | 36 | 57 | 197 |
| Total Other – Europe | 72 | 80 | 72 | 77 | 301 | 79 | 77 | 80 | 74 | 310 | 76 | 73 | 76 | 75 | 300 |
| Total Other – Rest of World | 58 | 78 | 62 | 56 | 255 | 71 | 88 | 68 | 52 | 280 | 81 | 77 | 72 | 72 | 302 |
| | <u>199</u> | <u>243</u> | <u>216</u> | <u>201</u> | <u>859</u> | <u>224</u> | <u>280</u> | <u>201</u> | <u>184</u> | <u>889</u> | <u>209</u> | <u>202</u> | <u>184</u> | <u>205</u> | <u>799</u> |
| Total product sales – U.S. | 4,434 | 4,777 | 4,985 | 5,180 | 19,377 | 4,609 | 4,916 | 5,433 | 5,550 | 20,508 | 4,631 | 5,038 | 5,274 | 5,873 | 20,816 |
| Total product sales – Europe | 1,053 | 999 | 1,017 | 1,128 | 4,197 | 1,144 | 1,118 | 1,154 | 1,160 | 4,576 | 1,073 | 1,178 | 1,144 | 1,221 | 4,617 |
| Total product sales – Rest of World | 819 | 788 | 992 | 762 | 3,361 | 894 | 878 | 928 | 826 | 3,526 | 909 | 838 | 928 | 808 | 3,483 |
| | <u>\$ 6,306</u> | <u>\$ 6,564</u> | <u>\$ 6,994</u> | <u>\$ 7,070</u> | <u>\$26,934</u> | <u>\$ 6,647</u> | <u>\$ 6,912</u> | <u>\$ 7,515</u> | <u>\$ 7,536</u> | <u>\$28,610</u> | <u>\$ 6,613</u> | <u>\$ 7,054</u> | <u>\$ 7,345</u> | <u>\$ 7,903</u> | <u>\$28,915</u> |

Certain amounts and percentages may not sum or recalculate due to rounding.

⁽⁵⁾ Includes Cayston, Jyseleca, Letairis and Zydelig.